Electrophysiologic therapeutics in heart failure in adult congenital heart disease

Heart Failure Clinics

Volumn 10, Issue 1, 2014, Pages 69-89

  Motonaga, Kara S ^a   Khairy, Paul ^b   Dubin, Anne M ^a  

^a STANFORD UNIVERSITY   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Adult congenital heart disease; Antiarrhythmics; Arrhythmias; Device therapy; Electrophysiology; Heart failure; Resynchronization; Therapeutics

Indexed keywords

AMIODARONE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; FLECAINIDE; METOPROLOL; PROPAFENONE; SOTALOL;

ABLATION THERAPY; ANTIARRHYTHMIC ACTIVITY; ARTIFICIAL HEART PACEMAKER; ATRIOPULMONARY CONNECTION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CONGENITAL HEART DISEASE; DEFIBRILLATION; DEVICE THERAPY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART RHYTHM; HEART SINGLE VENTRICLE; HEART VALVE REGURGITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONTRACTION; HEART VENTRICLE PERFORMANCE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTED HEART PACEMAKER; INOTROPISM; LIVER DYSFUNCTION; LUNG TOXICITY; MORBIDITY; NEUROLOGIC DISEASE; OPTIC NERVE DISEASE; PHOTOSENSITIVITY; PREVALENCE; PRIMARY PREVENTION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SECONDARY PREVENTION; SINUS BRADYCARDIA; SINUS NODE DISEASE; SUDDEN CARDIAC DEATH; SUPRAVENTRICULAR TACHYCARDIA;

ADULT CONGENITAL HEART DISEASE; ANTIARRHYTHMICS; ARRHYTHMIAS; DEVICE THERAPY; ELECTROPHYSIOLOGY; HEART FAILURE; RESYNCHRONIZATION; THERAPEUTICS;

ADULT; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIAC SURGICAL PROCEDURES; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PACEMAKER, ARTIFICIAL; SURVIVAL ANALYSIS;

EID: 84888032378     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.09.011     Document Type: Review

References (219)

1. Marelli A.J., Mackie A.S., Ionescu-Ittu R., et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007, 115:163-172.
2. Khairy P., Ionescu-Ittu R., Mackie A.S., et al. Changing mortality in congenital heart disease. JAm Coll Cardiol 2010, 56:1149-1157.
3. Zomer A.C., Vaartjes I., Uiterwaal C.S., et al. Circumstances of death in adult congenital heart disease. Int J Cardiol 2012, 154:168-172.
4. Zomer A.C., Uiterwaal C.S., van der Velde E.T., et al. Mortality in adult congenital heart disease: are national registries reliable for cause of death?. Int J Cardiol 2011, 152:212-217.
5. Verheugt C.L., Uiterwaal C.S., van der Velde E.T., et al. Mortality in adult congenital heart disease. Eur Heart J 2010, 31:1220-1229.
6. Oechslin E.N., Harrison D.A., Connelly M.S., et al. Mode of death in adults with congenital heart disease. Am J Cardiol 2000, 86:1111-1116.
7. Rodriguez F.H., Moodie D.S., Parekh D.R., et al. Outcomes of heart failure-related hospitalization in adults with congenital heart disease in the united states. Congenit Heart Dis 2012, [Epub ahead of print]. 10.1111/chd.12019.
8. Zomer A.C., Vaartjes I., van der Velde E.T., et al. Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol 2013, [Epub ahead of print]. 10.1016/j.ijcard.2013.03.003.
9. Fishberger S.B., Wernovsky G., Gentles T.L., et al. Factors that influence the development of atrial flutter after the Fontan operation. JThorac Cardiovasc Surg 1997, 113:80-86.
10. Flinn C.J., Wolff G.S., Dick M., et al. Cardiac rhythm after the Mustard operation for complete transposition of the great arteries. NEngl J Med 1984, 310:1635-1638.
11. Ghai A., Harris L., Harrison D.A., et al. Outcomes of late atrial tachyarrhythmias in adults after the Fontan operation. JAm Coll Cardiol 2001, 37:585-592.
12. Manning P.B., Mayer J.E., Wernovsky G., et al. Staged operation to Fontan increases the incidence of sinoatrial node dysfunction. JThorac Cardiovasc Surg 1996, 111:833-839. [discussion: 839-40].
13. Khairy P., Landzberg M.J., Lambert J., et al. Long-term outcomes after the atrial switch for surgical correction of transposition: a meta-analysis comparing the Mustard and Senning procedures. Cardiol Young 2004, 14:284-292.
14. Kammeraad J.A., van Deurzen C.H., Sreeram N., et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. JAm Coll Cardiol 2004, 44:1095-1102.
15. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013, 127:e283-e352.
16. Huhta J.C., Maloney J.D., Ritter D.G., et al. Complete atrioventricular block in patients with atrioventricular discordance. Circulation 1983, 67:1374-1377.
17. Anderson J.B., Czosek R.J., Knilans T.K., et al. Postoperative heart block in children with common forms of congenital heart disease: results from the KID database. JCardiovasc Electrophysiol 2012, 23:1349-1354.
18. Gross G.J., Chiu C.C., Hamilton R.M., et al. Natural history of postoperative heart block in congenital heart disease: implications for pacing intervention. Heart Rhythm 2006, 3:601-604.
19. Lillehei C.W., Sellers R.D., Bonnabeau R.C., et al. Chronic postsurgical complete heart block. With particular reference to prognosis, management, and a new P-wave pacemaker. JThorac Cardiovasc Surg 1963, 46:436-456.
20. Weindling S.N., Saul J.P., Gamble W.J., et al. Duration of complete atrioventricular block after congenital heart disease surgery. Am J Cardiol 1998, 82:525-527.
21. Bar-Cohen Y., Berul C.I., Alexander M.E., et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. JCardiovasc Electrophysiol 2006, 17:754-759.
22. Khairy P. EP challenges in adult congenital heart disease. Heart Rhythm 2008, 5:1464-1472.
23. Khairy P., Landzberg M.J., Gatzoulis M.A., et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation 2006, 113:2391-2397.
24. Nothroff J., Norozi K., Alpers V., et al. Pacemaker implantation as a risk factor for heart failure in young adults with congenital heart disease. Pacing Clin Electrophysiol 2006, 29:386-392.
25. Fortescue E.B., Berul C.I., Cecchin F., et al. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm 2004, 1:150-159.
26. Khairy P., Roux J.F., Dubuc M., et al. Laser lead extraction in adult congenital heart disease. JCardiovasc Electrophysiol 2007, 18:507-511.
27. Walsh E.P., Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007, 115:534-545.
28. Nakagawa H., Shah N., Matsudaira K., et al. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after surgical repair of congenital heart disease: isolated channels between scars allow "focal" ablation. Circulation 2001, 103:699-709.
29. Kalman J.M., VanHare G.F., Olgin J.E., et al. Ablation of 'incisional' reentrant atrial tachycardia complicating surgery for congenital heart disease. Use of entrainment to define a critical isthmus of conduction. Circulation 1996, 93:502-512.
30. Triedman J.K., Jenkins K.J., Colan S.D., et al. Intra-atrial reentrant tachycardia after palliation of congenital heart disease: characterization of multiple macroreentrant circuits using fluoroscopically based three-dimensional endocardial mapping. JCardiovasc Electrophysiol 1997, 8:259-270.
31. Triedman J.K., Alexander M.E., Berul C.I., et al. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia. Circulation 2001, 103:2060-2065.
32. Love B.A., Collins K.K., Walsh E.P., et al. Electroanatomic characterization of conduction barriers in sinus/atrially paced rhythm and association with intra-atrial reentrant tachycardia circuits following congenital heart disease surgery. JCardiovasc Electrophysiol 2001, 12:17-25.
33. Mandapati R., Walsh E.P., Triedman J.K. Pericaval and periannular intra-atrial reentrant tachycardias in patients with congenital heart disease. JCardiovasc Electrophysiol 2003, 14:119-125.
34. Collins K.K., Love B.A., Walsh E.P., et al. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol 2000, 86:969-974.
35. Delacretaz E., Ganz L.I., Soejima K., et al. Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. JAm Coll Cardiol 2001, 37:1665-1676.
36. Akar J.G., Kok L.C., Haines D.E., et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. JAm Coll Cardiol 2001, 38:377-384.
37. Khairy P., Harris L., Landzberg M.J., et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol 2008, 1:250-257.
38. Bartz P.J., Driscoll D.J., Dearani J.A., et al. Early and late results of the modified Fontan operation for heterotaxy syndrome 30 years of experience in 142 patients. JAm Coll Cardiol 2006, 48:2301-2305.
39. Cecchin F., Johnsrude C.L., Perry J.C., et al. Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol 1995, 76:386-391.
40. Gelatt M., Hamilton R.M., McCrindle B.W., et al. Risk factors for atrial tachyarrhythmias after the Fontan operation. JAm Coll Cardiol 1994, 24:1735-1741.
41. Nurnberg J.H., Ovroutski S., Alexi-Meskishvili V., et al. New onset arrhythmias after the extracardiac conduit Fontan operation compared with the intraatrial lateral tunnel procedure: early and midterm results. Ann Thorac Surg 2004, 78:1979-1988. [discussion: 1988].
42. Weber H.S., Hellenbrand W.E., Kleinman C.S., et al. Predictors of rhythm disturbances and subsequent morbidity after the Fontan operation. Am J Cardiol 1989, 64:762-767.
43. Roos-Hesselink J., Perlroth M.G., McGhie J., et al. Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic findings. Circulation 1995, 91:2214-2219.
44. Li W., Somerville J. Atrial flutter in grown-up congenital heart (GUCH) patients. Clinical characteristics of affected population. Int J Cardiol 2000, 75:129-137. [discussion: 138-9].
45. Wong T., Davlouros P.A., Li W., et al. Mechano-electrical interaction late after Fontan operation: relation between P-wave duration and dispersion, right atrial size, and atrial arrhythmias. Circulation 2004, 109:2319-2325.
46. Do D. Prevalence of atrial fibrillation in adult congenital heart disease. Heart Rhythm 2013, 10:S45. [abstract].
47. Khairy P., Aboulhosn J., Gurvitz M.Z., et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010, 122:868-875.
48. Kirsh J.A., Walsh E.P., Triedman J.K. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol 2002, 90:338-340.
49. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. JAm Coll Cardiol 2011, 57:e101-e198.
50. Walsh E.P. Interventional electrophysiology in patients with congenital heart disease. Circulation 2007, 115:3224-3234.
51. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, [Epub ahead of print]. 10.1161/CIR.0b013e31829e8776.
52. Pratt C.M., Moye L.A. The cardiac arrhythmia suppression trial: background, interim results and implications. Am J Cardiol 1990, 65:20B-29B.
53. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. NEngl J Med 1991, 324:781-788.
54. Fish F.A., Gillette P.C., Benson D.W. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. JAm Coll Cardiol 1991, 18:356-365.
55. Janousek J., Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 1998, 81:1121-1124.
56. Tanel R.E., Walsh E.P., Lulu J.A., et al. Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. Am Heart J 1995, 130:791-797.
57. Beaufort-Krol G.C., Bink-Boelkens M.T. Sotalol for atrial tachycardias after surgery for congenital heart disease. Pacing Clin Electrophysiol 1997, 20:2125-2129.
58. Beaufort-Krol G.C., Bink-Boelkens M.T. Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. Am J Cardiol 1997, 79:92-94.
59. Miyazaki A., Ohuchi H., Kurosaki K., et al. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 2008, 72:1998-2003.
60. Rao S.O., Boramanand N.K., Burton D.A., et al. Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol. Int J Cardiol 2009, 136:253-257.
61. Pfammatter J.P., Paul T., Lehmann C., et al. Efficacy and proarrhythmia of oral sotalol in pediatric patients. JAm Coll Cardiol 1995, 26:1002-1007.
62. Zimetbaum P. Amiodarone for atrial fibrillation. NEngl J Med 2007, 356:935-941.
63. Coumel P., Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J 1980, 100:1063-1069.
64. Villain E. Amiodarone as treatment for atrial tachycardias after surgery. Pacing Clin Electrophysiol 1997, 20:2130-2132.
65. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. NEngl J Med 1995, 333:77-82.
66. Thorne S.A., Barnes I., Cullinan P., et al. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 1999, 100:149-154.
67. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. NEngl J Med 2000, 342:913-920.
68. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. NEngl J Med 2005, 352:1861-1872.
69. Perry J.C., Garson A. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J 1992, 124:1614-1621.
70. Zarembski D.G., Nolan P.E., Slack M.K., et al. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995, 155:1885-1891.
71. Naccarelli G.V., Wolbrette D.L., Khan M., et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003, 91:15D-26D.
72. Kochiadakis G.E., Marketou M.E., Igoumenidis N.E., et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing Clin Electrophysiol 2000, 23:1883-1887.
73. Chun S.H., Sager P.T., Stevenson W.G., et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995, 76:47-50.
74. Gosselink A., Crijns H.M., Van Gelder I.C., et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992, 267:3289-3293.
75. Khairy P., Balaji S. Cardiac arrhythmias in congenital heart diseases. Indian Pacing Electrophysiol J 2009, 9:299-317.
76. Triedman J.K., DeLucca J.M., Alexander M.E., et al. Prospective trial of electroanatomically guided, irrigated catheter ablation of atrial tachycardia in patients with congenital heart disease. Heart Rhythm 2005, 2:700-705.
77. Triedman J.K., Alexander M.E., Love B.A., et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. JAm Coll Cardiol 2002, 39:1827-1835.
78. Triedman J.K., Bergau D.M., Saul J.P., et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. JAm Coll Cardiol 1997, 30:1032-1038.
79. Mondesert B., Abadir S., Khairy P. Arrhythmias in adult congenital heart disease: the year in review. Curr Opin Cardiol 2013, 28:354-359.
80. Ernst S. Robotic approach to catheter ablation. Curr Opin Cardiol 2008, 23:28-31.
81. Wu J., Pflaumer A., Deisenhofer I., et al. Mapping ofintraatrial reentrant tachycardias by remote magnetic navigation in patients with d-transposition of the great arteries after Mustard or Senning procedure. JCardiovasc Electrophysiol 2008, 19:1153-1159.
82. Wu J., Pflaumer A., Deisenhofer I., et al. Mapping of atrial tachycardia by remote magnetic navigation in postoperative patients with congenital heart disease. JCardiovasc Electrophysiol 2010, 21:751-759.
83. Ernst S., Babu-Narayan S.V., Keegan J., et al. Remote-controlled magnetic navigation and ablation with 3D image integration as an alternative approach in patients with intra-atrial baffle anatomy. Circ Arrhythm Electrophysiol 2012, 5:131-139.
84. Calkins H., Kuck K.H., Cappato R., et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012, 14:528-606.
85. Philip F., Muhammad K.I., Agarwal S., et al. Pulmonary vein isolation for the treatment of drug-refractory atrial fibrillation in adults with congenital heart disease. Congenit Heart Dis 2012, 7:392-399.
86. Rhodes L.A., Walsh E.P., Gamble W.J., et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol 1995, 18:1005-1016.
87. Ragonese P., Drago F., Guccione P., et al. Permanent overdrive atrial pacing in the chronic management of recurrent postoperative atrial reentrant tachycardia in patients with complex congenital heart disease. Pacing Clin Electrophysiol 1997, 20:2917-2923.
88. Stephenson E.A., Casavant D., Tuzi J., et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol 2003, 92:871-876.
89. El Yaman M.M., Asirvatham S.J., Kapa S., et al. Methods to access the surgically excluded cavotricuspid isthmus for complete ablation of typical atrial flutter in patients with congenital heart defects. Heart Rhythm 2009, 6:949-956.
90. Mavroudis C., Backer C.L., Deal B.J., et al. Total cavopulmonary conversion and maze procedure for patients with failure of the Fontan operation. JThorac Cardiovasc Surg 2001, 122:863-871.
91. Backer C.L., Tsao S., Deal B.J., et al. Maze procedure in single ventricle patients. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2008, 11:44-48.
92. Deal B.J., Mavroudis C., Backer C.L. Beyond Fontan conversion: surgical therapy of arrhythmias including patients with associated complex congenital heart disease. Ann Thorac Surg 2003, 76:542-553. [discussion: 553-4].
93. Deal B.J., Mavroudis C., Backer C.L., et al. Impact of arrhythmia circuit cryoablation during Fontan conversion for refractory atrial tachycardia. Am J Cardiol 1999, 83:563-568.
94. Mavroudis C., Backer C.L., Deal B.J., et al. Fontan conversion to cavopulmonary connection and arrhythmia circuit cryoblation. JThorac Cardiovasc Surg 1998, 115:547-556.
95. Mavroudis C., Deal B.J., Backer C.L. The beneficial effects of total cavopulmonary conversion and arrhythmia surgery for the failed Fontan. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002, 5:12-24.
96. Mavroudis C., Deal B.J., Backer C.L. Arrhythmia surgery in association with complex congenital heart repairs excluding patients with Fontan conversion. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2003, 6:33-50.
97. Mavroudis C., Deal B.J., Backer C.L. Surgery for arrhythmias in children. Int J Cardiol 2004, 97(Suppl 1):39-51.
98. Mavroudis C., Deal B.J., Backer C.L., et al. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg 2007, 84:1457-1466.
99. Mavroudis C., Deal B.J., Backer C.L., et al. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg 2008, 86:857-868.
100. Collins K.K., Rhee E.K., Delucca J.M., et al. Modification to the Fontan procedure for the prophylaxis of intra-atrial reentrant tachycardia: short-term results of a prospective randomized blinded trial. JThorac Cardiovasc Surg 2004, 127:721-729.
101. Sheikh A.M., Tang A.T., Roman K., et al. The failing Fontan circulation: successful conversion of atriopulmonary connections. JThorac Cardiovasc Surg 2004, 128:60-66.
102. Weinstein S., Cua C., Chan D., et al. Outcome of symptomatic patients undergoing extracardiac Fontan conversion and cryoablation. JThorac Cardiovasc Surg 2003, 126:529-536.
103. Therrien J., Dore A., Gersony W., et al. CCS consensus conference 2001 update: recommendations for the management of adults with congenital heart disease. Part I. Can J Cardiol 2001, 17:940-959.
104. Khairy P., Poirier N., Mercier L.A. Univentricular heart. Circulation 2007, 115:800-812.
105. Nieminen H.P., Jokinen E.V., Sairanen H.I. Causes of late deaths after pediatric cardiac surgery: a population-based study. JAm Coll Cardiol 2007, 50:1263-1271.
106. Silka M.J., Hardy B.G., Menashe V.D., et al. Apopulation-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. JAm Coll Cardiol 1998, 32:245-251.
107. Sullivan I.D., Presbitero P., Gooch V.M., et al. Is ventricular arrhythmia in repaired tetralogy of Fallot an effect of operation or a consequence of the course of the disease? A prospective study. BrHeart J 1987, 58:40-44.
108. Deanfield J.E., Ho S.Y., Anderson R.H., et al. Late sudden death after repair of tetralogy of Fallot: a clinicopathologic study. Circulation 1983, 67:626-631.
109. Shiga T., Kasanuki H. Drug therapy for ventricular tachyarrhythmia in heart failure. Circ J 2007, 71(Suppl A):A90-A96.
110. Harrison D.A., Harris L., Siu S.C., et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. JAm Coll Cardiol 1997, 30:1368-1373.
111. Murphy J.G., Gersh B.J., Mair D.D., et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. NEngl J Med 1993, 329:593-599.
112. Gatzoulis M.A., Till J.A., Somerville J., et al. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 1995, 92:231-237.
113. Gatzoulis M.A., Balaji S., Webber S.A., et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000, 356:975-981.
114. Berul C.I., Hill S.L., Geggel R.L., et al. Electrocardiographic markers of late sudden death risk in postoperative tetralogy of Fallot children. JCardiovasc Electrophysiol 1997, 8:1349-1356.
115. Horowitz L.N., Vetter V.L., Harken A.H., et al. Electrophysiologic characteristics of sustained ventricular tachycardia occurring after repair of tetralogy of Fallot. Am J Cardiol 1980, 46:446-452.
116. Downar E., Harris L., Kimber S., et al. Ventricular tachycardia after surgical repair of tetralogy of Fallot: results of intraoperative mapping studies. JAm Coll Cardiol 1992, 20:648-655.
117. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
118. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344:1651-1658.
119. Connolly S.J. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 1999, 84:90R-93R.
120. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993, 270:1589-1595.
121. Rusconi P., Gomez-Marin O., Rossique-Gonzalez M., et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. JHeart Lung Transplant 2004, 23:832-838.
122. Azeka E., Franchini Ramires J.A., Valler C., et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. JAm Coll Cardiol 2002, 40:2034-2038.
123. Bruns L.A., Chrisant M.K., Lamour J.M., et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. JPediatr 2001, 138:505-511.
124. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. NEngl J Med 1996, 334:1349-1355.
125. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
126. Hjalmarson A., Fagerberg B. MERIT-HF mortality and morbidity data. Basic Res Cardiol 2000, 95(Suppl 1):I98-I103.
127. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
128. Torp-Pedersen C., Poole-Wilson P.A., Swedberg K., et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure-COMET. Am Heart J 2005, 149:370-376.
129. Connolly S.J. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999, 100:2025-2034.
130. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997, 350:1417-1424.
131. Gonska B.D., Cao K., Raab J., et al. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation 1996, 94:1902-1908.
132. Morwood J.G., Triedman J.K., Berul C.I., et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 2004, 1:301-308.
133. Furushima H., Chinushi M., Sugiura H., et al. Ventricular tachycardia late after repair of congenital heartdisease: efficacy of combination therapy with radiofrequency catheter ablation and class III antiarrhythmic agents and long-term outcome. JElectrocardiol 2006, 39:219-224.
134. Kriebel T., Saul J.P., Schneider H., et al. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. JAm Coll Cardiol 2007, 50:2162-2168.
135. Zeppenfeld K., Schalij M.J., Bartelings M.M., et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007, 116:2241-2252.
136. Tokuda M., Tedrow U.B., Kojodjojo P., et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol 2012, 5:992-1000.
137. Khairy P., Stevenson W.G. Catheter ablation in tetralogy of Fallot. Heart Rhythm 2009, 6:1069-1074.
138. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008, 117:e350-e408.
139. Alexander M.E., Cecchin F., Walsh E.P., et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. JCardiovasc Electrophysiol 2004, 15:72-76.
140. Dore A., Santagata P., Dubuc M., et al. Implantable cardioverter defibrillators in adults with congenital heart disease: a single center experience. Pacing Clin Electrophysiol 2004, 27:47-51.
141. Yap S.C., Roos-Hesselink J.W., Hoendermis E.S., et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J 2007, 28:1854-1861.
142. Khairy P., Harris L., Landzberg M.J., et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008, 117:363-370.
143. Witte K.K., Pepper C.B., Cowan J.C., et al. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace 2008, 10:926-930.
144. Khanna A.D., Warnes C.A., Phillips S.D., et al. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease. Am J Cardiol 2011, 108:729-734.
145. Koyak Z., de Groot J.R., Van Gelder I.C., et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks?. Circ Arrhythm Electrophysiol 2012, 5:101-110.
146. Uyeda T., Inoue K., Sato J., et al. Outcome of implantable cardioverter defibrillator therapy for congenital heart disease. Pediatr Int 2012, 54:379-382.
147. Korte T., Koditz H., Niehaus M., et al. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004, 27:924-932.
148. Berul C.I., Van Hare G.F., Kertesz N.J., et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. JAm Coll Cardiol 2008, 51:1685-1691.
149. Khairy P., Mansour F. Implantable cardioverter-defibrillators in congenital heart disease: 10 programming tips. Heart Rhythm 2011, 8:480-483.
150. Lee C.H., Nam G.B., Park H.G., et al. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. Circ J 2008, 72:102-105.
151. Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA 2006, 295:165-171.
152. Ferreira-Gonzalez I., Dos-Subira L., Guyatt G.H. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 2007, 28:469-477.
153. Wathen M.S., DeGroot P.J., Sweeney M.O., et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: pacing fast ventricular tachycardia reduces shock therapies (PainFREE Rx II) trial results. Circulation 2004, 110:2591-2596.
154. Wathen M. Implantable cardioverter defibrillator shock reduction using new antitachycardia pacing therapies. Am Heart J 2007, 153:44-52.
155. Stephenson E.A., Batra A.S., Knilans T.K., et al. Amulticenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. JCardiovasc Electrophysiol 2006, 17:41-46.
156. Kaltman J.R., Gaynor J.W., Rhodes L.A., et al. Subcutaneous array with active can implantable cardioverter defibrillator configuration: a follow-up study. Congenit Heart Dis 2007, 2:125-129.
157. Tomaske M., Pretre R., Rahn M., et al. Epicardial and pleural lead ICD systems in children and adolescents maintain functionality over 5 years. Europace 2008, 10:1152-1156.
158. Bardy G.H., Smith W.M., Hood M.A., et al. An entirely subcutaneous implantable cardioverter-defibrillator. NEngl J Med 2010, 363:36-44.
159. Dabiri Abkenari L., Theuns D.A., Valk S.D., et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 2011, 100:737-744.
160. Gold M.R., Theuns D.A., Knight B.P., et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. JCardiovasc Electrophysiol 2012, 23:359-366.
161. Kobe J., Reinke F., Meyer C., et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013, 10:29-36.
162. Olde Nordkamp L.R., Dabiri Abkenari L., Boersma L.V., et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. JAm Coll Cardiol 2012, 60:1933-1939.
163. Jarman J.W., Lascelles K., Wong T., et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J 2012, 33:1351-1359.
164. Aydin A., Hartel F., Schluter M., et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol 2012, 5:913-919.
165. Weiss R., Knight B.P., Gold M.R., et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013, 128:944-953.
166. Peters B., Will A., Berger F., et al. Implantation of a fully subcutaneous ICD in a patient with single ventricle morphology and Eisenmenger physiology. Acta Cardiol 2012, 67:473-475.
167. Calvo N., Arguedas H., Lopez G., et al. Totally subcutaneous ICD implantation as an alternative to the conventional ICD in a patient with a congenital cardiopathy. Rev Esp Cardiol 2013, 66:827-829.
168. Therrien J., Siu S.C., Harris L., et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001, 103:2489-2494.
169. Karamlou T., Silber I., Lao R., et al. Outcomes after late reoperation in patients with repaired tetralogy of Fallot: the impact of arrhythmia and arrhythmia surgery. Ann Thorac Surg 2006, 81:1786-1793. [discussion: 1793].
170. Abraham W.T., Fisher W.G., Smith A.L., Miracle Study Group.Multicenter InSync Randomized Clinical Evaluation, et al. Cardiac resynchronization in chronic heart failure. NEngl J Med 2002, 346:1845-1853.
171. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. NEngl J Med 2001, 344:873-880.
172. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. JAm Coll Cardiol 2003, 42:1454-1459.
173. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. NEngl J Med 2004, 350:2140-2150.
174. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. NEngl J Med 2005, 352:1539-1549.
175. Linde C., Ellenbogen K., McAlister F.A. Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations. Heart Rhythm 2012, 9:S3-S13.
176. Stahlberg M., Lund L.H., Zabarovskaja S., et al. Cardiac resynchronization therapy: a breakthrough in heart failure management. JIntern Med 2012, 272:330-343.
177. Alexander M.E., Berul C.I., Fortescue E.B., et al. Who is eligible for cardiac resynchronization therapy in pediatric cardiology?. Heart Rhythm 2004, 1:S122-S123. [abstract].
178. Rodriguez-Cruz E., Karpawich P.P., Lieberman R.A., et al. Biventricular pacing as alternative therapy for dilated cardiomyopathy associated with congenital heart disease. Pacing Clin Electrophysiol 2001, 24:235-237.
179. Roofthooft M.T., Blom N.A., Rijlaarsdam M.E., et al. Resynchronization therapy after congenital heart surgery to improve left ventricular function. Pacing Clin Electrophysiol 2003, 26:2042-2044.
180. Blom N.A., Bax J.J., Ottenkamp J., et al. Transvenous biventricular pacing in a child after congenital heart surgery as an alternative therapy for congestive heart failure. JCardiovasc Electrophysiol 2003, 14:1110-1112.
181. Senzaki H., Kyo S., Matsumoto K., et al. Cardiac resynchronization therapy in a patient with single ventricle and intracardiac conduction delay. JThorac Cardiovasc Surg 2004, 127:287-288.
182. Janousek J., Tomek V., Chaloupecky V., et al. Dilated cardiomyopathy associated with dual-chamber pacing in infants: improvement through either left ventricular cardiac resynchronization or programming the pacemaker off allowing intrinsic normal conduction. JCardiovasc Electrophysiol 2004, 15:470-474.
183. Cowburn P.J., Parker J.D., Cameron D.A., et al. Cardiac resynchronization therapy: retiming the failing right ventricle. JCardiovasc Electrophysiol 2005, 16:439-443.
184. Kakavand B., Douglas W.I., Manfredi J.A., et al. Successful management of acute failure of the systemic right ventricle with cardiac resynchronization therapy. Pediatr Cardiol 2006, 27:612-613.
185. van Beek E., Backx A., Singh S. Cardiac resynchronization as therapy for congestive cardiac failure in children dependent on chronic cardiac pacing. Cardiol Young 2006, 16:187-189.
186. Chen C.A., Wang S.S., Chiu S.N., et al. Left ventricular reverse remodeling after successful cardiac resynchronization therapy in a 3-year-old girl with idiopathic dilated cardiomyopathy. Int J Cardiol 2007, 117:e7-e9.
187. Gonzalez M.B., Schweigel J., Kostelka M., et al. Cardiac resynchronization in a child with dilated cardiomyopathy and borderline QRS duration: speckle tracking guided lead placement. Pacing Clin Electrophysiol 2009, 32:683-687.
188. Ortega M., Merino J.L., Blanco F.V., et al. Cardiac resynchronization therapy in an infant with double outlet right ventricle and mechanical dyssynchrony. JCardiovasc Electrophysiol 2012, 23:781-783.
189. Hauser J., Michel-Behnke I., Khazen C., et al. Successful cardiac resynchronization therapy in a 1.5-year-old girl with dilated cardiomyopathy and functional mitral regurgitation. Int J Cardiol 2013, 167:e83-e84.
190. Janousek J., Tomek V., Chaloupecky V.A., et al. Cardiac resynchronization therapy: a novel adjunct to the treatment and prevention of systemic right ventricular failure. JAm Coll Cardiol 2004, 44:1927-1931.
191. Strieper M., Karpawich P., Frias P., et al. Initial experience with cardiac resynchronization therapy for ventricular dysfunction in young patients with surgically operated congenital heart disease. Am J Cardiol 2004, 94:1352-1354.
192. Moak J.P., Hasbani K., Ramwell C., et al. Dilated cardiomyopathy following right ventricular pacing for AV block in young patients: resolution after upgrading to biventricular pacing systems. JCardiovasc Electrophysiol 2006, 17:1068-1071.
193. Khairy P., Fournier A., Thibault B., et al. Cardiac resynchronization therapy in congenital heart disease. Int J Cardiol 2006, 109:160-168.
194. Jauvert G., Rousseau-Paziaud J., Villain E., et al. Effects of cardiac resynchronization therapy on echocardiographic indices, functional capacity, and clinical outcomes of patients with a systemic right ventricle. Europace 2009, 11:184-190.
195. Cecchin F., Frangini P.A., Brown D.W., et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. JCardiovasc Electrophysiol 2009, 20:58-65.
196. Perera J.L., Motonaga K.S., Miyake C.Y., et al. Does pediatric CRT increase the risk of ventricular tachycardia?. Heart Rhythm 2013, 10:S210-S211. [abstract].
197. Dubin A.M., Janousek J., Rhee E., et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. JAm Coll Cardiol 2005, 46:2277-2283.
198. Janousek J., Gebauer R.A., Abdul-Khaliq H., Working Group for Cardiac Dysrhythmias and Electrophysiology of the Association for European Paediatric Cardiology, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009, 95:1165-1171.
199. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. NEngl J Med 2009, 361:1329-1338.
200. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the miracle ICD trial. JAMA 2003, 289:2685-2694.
201. Bhatta L., Luck J.C., Wolbrette D.L., et al. Complications of biventricular pacing. Curr Opin Cardiol 2004, 19:31-35.
202. Thibault B., Harel F., Ducharme A., et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation 2013, 127:873-881.
203. Valls-Bertault V., Fatemi M., Gilard M., et al. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace 2004, 6:438-443.
204. Leon A.R., Greenberg J.M., Kanuru N., et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. JAm Coll Cardiol 2002, 39:1258-1263.
205. Helbing W.A., Rebergen S.A., Maliepaard C., et al. Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. Am Heart J 1995, 130:828-837.
206. Janousek J., Vojtovic P., Hucin B., et al. Resynchronization pacing is a useful adjunct to the management of acute heart failure after surgery for congenital heart defects. Am J Cardiol 2001, 88:145-152.
207. Dubin A.M., Feinstein J.A., Reddy V.M., et al. Electrical resynchronization: a novel therapy for the failing right ventricle. Circulation 2003, 107:2287-2289.
208. Dubin A.M., Hanisch D., Chin C., et al. Aprospective pilot study of right ventricular resynchronization. Heart Rhythm 2008, 5:S42. [abstract].
209. Thambo J.B., De Guillebon M., Xhaet O., et al. Biventricular pacing in patients with tetralogy of Fallot:non-invasive epicardial mapping and clinical impact. Int J Cardiol 2011, 30:30.
210. Thambo J.B., Dos Santos P., De Guillebon M., et al. Biventricular stimulation improves right and left ventricular function after tetralogy of Fallot repair: acute animal and clinical studies. Heart Rhythm 2010, 7:344-350.
211. Rosenthal D., Chrisant M.R., Edens E., et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. JHeart Lung Transplant 2004, 23:1313-1333.
212. Lubiszewska B., Gosiewska E., Hoffman P., et al. Myocardial perfusion and function of the systemic right ventricle in patients after atrial switch procedure for complete transposition: long-term follow-up. JAm Coll Cardiol 2000, 36:1365-1370.
213. Millane T., Bernard E.J., Jaeggi E., et al. Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposition of the great arteries. JAm Coll Cardiol 2000, 35:1661-1668.
214. Pettersen E., Helle-Valle T., Edvardsen T., et al. Contraction pattern of the systemic right ventricle shift from longitudinal to circumferential shortening and absent global ventricular torsion. JAm Coll Cardiol 2007, 49:2450-2456.
215. Redington A.N., Rigby M.L., Oldershaw P., et al. Right ventricular function 10 years after the Mustard operation for transposition of the great arteries: analysis of size, shape, and wall motion. Br Heart J 1989, 62:455-461.
216. Fogel M.A., Weinberg P.M., Fellows K.E., et al. Astudy in ventricular-ventricular interaction. Single right ventricles compared with systemic right ventricles in a dual-chamber circulation. Circulation 1995, 92:219-230.
217. Singh T.P., Humes R.A., Muzik O., et al. Myocardial flow reserve in patients with a systemic right ventricle after atrial switch repair. JAm Coll Cardiol 2001, 37:2120-2125.
218. Zimmerman F.J., Starr J.P., Koenig P.R., et al. Acute hemodynamic benefit of multisite ventricular pacing after congenital heart surgery. Ann Thorac Surg 2003, 75:1775-1780.
219. Bacha E.A., Zimmerman F.J., Mor-Avi V., et al. Ventricular resynchronization by multisite pacing improves myocardial performance in the postoperative single-ventricle patient. Ann Thorac Surg 2004, 78:1678-1683.